Suppression of thrombospondin-1 expression during uveal melanoma progression and its potential therapeutic utility

Archives of Ophthalmology

Volumn 130, Issue 3, 2012, Pages 336-341

  Wang, Shoujian ^a   Neekhra, Aneesh ^a   Albert, Daniel M ^a   Sorenson, Christine M ^a   Sheibani, Nader ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; THROMBOSPONDIN 1; THROMBOSPONDIN 1 MIMETIC PEPTIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; HISTOPATHOLOGY; IMMUNOHISTOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UVEA MELANOMA;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; MELANOMA; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; THROMBOSPONDIN 1; UVEAL NEOPLASMS;

EID: 84863363755     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archopthalmol.2011.1503     Document Type: Article

References (34)

1. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005;18(1):75-84, viii. (Pubitemid 40348812)
2. Sheibani N, Albert DM. Angiogenesis and ocular tumorigenesis. In: Tombran-Tank J, Barnstable CJ, eds. Ocular Angiogenesis: Diseases, Mechanisms, and Therapeutics. Totowa, NJ: Humana Press; 2006:161-171.
3. Ordonez JL, Paraoan L, Hiscott P, et al. Differential expression of angioregulatory matricellular proteins in posterior uveal melanoma. Melanoma Res. 2005;15(6):495-502. (Pubitemid 44124260)
4. van Ginkel PR, Gee RL, Shearer RL, et al. Expression of the receptor tyrosine kinase Axl promotes ocular melanoma cell survival. Cancer Res. 2004;64(1):128-134. (Pubitemid 38114090)
5. Missotten GS, Notting IC, Schlingemann RO, et al. Vascular endothelial growth factor A in eyes with uveal melanoma. Arch Ophthalmol. 2006;124(10):1428-1434. (Pubitemid 44537143)
6. Boyd SR, Tan D, Bunce C, et al. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol. 2002;86(4):448-452. (Pubitemid 34293296)
7. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18.
8. Good DJ, Polverini PJ, Rastinejad F, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A. 1990;87(17):6624-6628.
9. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994;265(5178):1582- 1584. (Pubitemid 24308973)
10. Lawler J. The functions of thrombospondin-1 and -2. Curr Opin Cell Biol. 2000;12(5):634-640.
11. Jiménez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N. Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med. 2000;6(1):41-48. (Pubitemid 30048524)
12. Sheibani N, Sorenson CM, Cornelius LA, Frazier WA. Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem Biophys Res Commun. 2000;267(1):257-261. (Pubitemid 30072539)
13. Wang S, Wu Z, Sorenson CM, Lawler J, Sheibani N. Thrombospondin-1- deficient mice exhibit increased vascular density during retinal vascular development and are less sensitive to hyperoxia-mediated vessel obliteration. Dev Dyn. 2003;228(4):630-642. (Pubitemid 37493982)
14. Wu Z, Wang S, Sorenson CM, Sheibani N. Attenuation of retinal vascular development and neovascularization in transgenic mice over-expressing thrombospondin-1 in the lens. Dev Dyn. 2006;235(7):1908-1920. (Pubitemid 43902348)
15. el Filali M, Missotten GS, Maat W, et al. Regulation of VEGF-A in uveal melanoma. Invest Ophthalmol Vis Sci. 2010;51(5):2329-2337.
16. Yang H, Jager MJ, Grossniklaus HE. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci. 2010;51(6):2835-2842.
17. Yang H, Xu Z, Iuvone PM, Grossniklaus HE. Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) to pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model. Mol Vis. 2006;12:511-517. (Pubitemid 43778949)
18. Yang H, Grossniklaus HE. Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasis. Invest Ophthalmol Vis Sci. 2010;51(1):28-34.
19. Syed NA, Windle JJ, Darjatmoko SR, et al. Transgenic mice with pigmented intraocular tumors: tissue of origin and treatment. Invest Ophthalmol Vis Sci. 1998;39(13):2800-2805. (Pubitemid 28558244)
20. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol. 1993;122(2):497-511. (Pubitemid 23210475)
21. Dawson DW, Volpert OV, Pearce SF, et al. Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat. Mol Pharmacol. 1999;55(2):332-338. (Pubitemid 29076031)
22. Garside SA, Henkin J, Morris KD, Norvell SM, Thomas FH, Fraser HM. A thrombospondin-mimetic peptide, ABT-898, suppresses angiogenesis and promotes follicular atresia in pre- and early-antral follicles in vivo. Endocrinology. 2010;151(12):5905-5915.
23. Wilkerson CL, Darjatmoko SR, Lindstrom MJ, Albert DM. Toxicity and doseresponse studies of 1,25-(OH)2-16-ene-23-yne vitamin D3 in transgenic mice. Clin Cancer Res. 1998;4(9):2253-2256. (Pubitemid 28415674)
24. Grostern RJ, Bryar PJ, Zimbric ML, et al. Toxicity and dose-response studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model. Arch Ophthalmol. 2002;120(5):607-612. (Pubitemid 34496612)
25. Dawson DG, Gleiser J, Zimbric ML, et al. Toxicity and dose-response studies of 1-alpha hydroxyvitamin D2 in LH-beta-tag transgenic mice. Ophthalmology. 2003;110(4):835-839. (Pubitemid 36520089)
26. Sheibani N, Sorenson CM, Frazier WA. Tissue specific expression of alternatively spliced murine PECAM-1 isoforms. Dev Dyn. 1999;214(1):44-54. (Pubitemid 29028902)
27. Stitt AW, Gardiner TA. Anti-angiogenic therapy for uveal melanoma: more haste, less speed. Br J Ophthalmol. 2002;86(4):368-369. (Pubitemid 34293279)
28. Chana JS, Wilson GD, Cree IA, et al. c-myc, p53, and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol. 1999;83(1):110-114. (Pubitemid 29106343)
29. Brantley MA Jr, Harbour JW. Deregulation of the Rb and p53 pathways in uveal melanoma. Am J Pathol. 2000;157(6):1795-1801.
30. Edmunds SC, Kelsell DP, Hungerford JL, Cree IA. Mutational analysis of selected genes in the TGFbeta, Wnt, pRb, and p53 pathways in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2002;43(9):2845-2851. (Pubitemid 34977031)
31. Scholes AG, Liloglou T, Maloney P, et al. Loss of heterozygosity on chromosomes 3, 9, 13, and 17, including the retinoblastoma locus, in uveal melanoma. Invest Ophthalmol Vis Sci. 2001;42(11):2472-2477. (Pubitemid 32954850)
32. Chowers I, Folberg R, Livni N, Pe'er J. p53 Immunoreactivity, Ki-67 expression, and microcirculation patterns in melanoma of the iris, ciliary body, and choroid. Curr Eye Res. 2002;24(2):105-108. (Pubitemid 34775527)
33. Jay M, McCartney AC. Familial malignant melanoma of the uvea and p53: a Victorian detective story. Surv Ophthalmol. 1993;37(6):457-462. (Pubitemid 23144014)
34. Kishore K, Ghazvini S, Char DH, Kroll S, Selle J. p53 gene and cell cycling in uveal melanoma. Am J Ophthalmol. 1996;121(5):561-567. (Pubitemid 26135865)